Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
- Author
- J-Y Reginster, Jean Kaufman (UGent) , Stefan Goemaere (UGent) , JP Devogelaer, CL Benhamou, D Felsenberg, M Diaz-Curiel, M-L Brandi, J Badurski, J Wark, A Balogh, O Bruyère and C Roux
- Organization
- Abstract
- In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years. Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAXA (R) scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAXA (R)-matched placebo group identified in the TROPOS placebo arm. The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 +/- 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAXA (R)-matched placebo group over 5 years (P < 0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years. Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a good safety profile. Our results also support the maintenance of antifracture efficacy over 10 years with strontium ranelate.
- Keywords
- CONTINUING OUTCOMES RELEVANT, Strontium ranelate, Long-term treatment, Osteoporotic fracture, BMD, EXTENSION, PROBABILITY, FRACTURE INTERVENTION TRIAL, VERTEBRAL FRACTURE, RANDOMIZED-TRIAL, WOMEN, RISK, LONG, ALENDRONATE
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 267.92 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-3091367
- MLA
- Reginster, J. Y., et al. “Maintenance of Antifracture Efficacy over 10 Years with Strontium Ranelate in Postmenopausal Osteoporosis.” OSTEOPOROSIS INTERNATIONAL, vol. 23, no. 3, 2012, pp. 1115–22, doi:10.1007/s00198-011-1847-z.
- APA
- Reginster, J.-Y., Kaufman, J., Goemaere, S., Devogelaer, J., Benhamou, C., Felsenberg, D., … Roux, C. (2012). Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. OSTEOPOROSIS INTERNATIONAL, 23(3), 1115–1122. https://doi.org/10.1007/s00198-011-1847-z
- Chicago author-date
- Reginster, J-Y, Jean Kaufman, Stefan Goemaere, JP Devogelaer, CL Benhamou, D Felsenberg, M Diaz-Curiel, et al. 2012. “Maintenance of Antifracture Efficacy over 10 Years with Strontium Ranelate in Postmenopausal Osteoporosis.” OSTEOPOROSIS INTERNATIONAL 23 (3): 1115–22. https://doi.org/10.1007/s00198-011-1847-z.
- Chicago author-date (all authors)
- Reginster, J-Y, Jean Kaufman, Stefan Goemaere, JP Devogelaer, CL Benhamou, D Felsenberg, M Diaz-Curiel, M-L Brandi, J Badurski, J Wark, A Balogh, O Bruyère, and C Roux. 2012. “Maintenance of Antifracture Efficacy over 10 Years with Strontium Ranelate in Postmenopausal Osteoporosis.” OSTEOPOROSIS INTERNATIONAL 23 (3): 1115–1122. doi:10.1007/s00198-011-1847-z.
- Vancouver
- 1.Reginster J-Y, Kaufman J, Goemaere S, Devogelaer J, Benhamou C, Felsenberg D, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. OSTEOPOROSIS INTERNATIONAL. 2012;23(3):1115–22.
- IEEE
- [1]J.-Y. Reginster et al., “Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis,” OSTEOPOROSIS INTERNATIONAL, vol. 23, no. 3, pp. 1115–1122, 2012.
@article{3091367, abstract = {{In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years. Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAXA (R) scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAXA (R)-matched placebo group identified in the TROPOS placebo arm. The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 +/- 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAXA (R)-matched placebo group over 5 years (P < 0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years. Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a good safety profile. Our results also support the maintenance of antifracture efficacy over 10 years with strontium ranelate.}}, author = {{Reginster, J-Y and Kaufman, Jean and Goemaere, Stefan and Devogelaer, JP and Benhamou, CL and Felsenberg, D and Diaz-Curiel, M and Brandi, M-L and Badurski, J and Wark, J and Balogh, A and Bruyère, O and Roux, C}}, issn = {{0937-941X}}, journal = {{OSTEOPOROSIS INTERNATIONAL}}, keywords = {{CONTINUING OUTCOMES RELEVANT,Strontium ranelate,Long-term treatment,Osteoporotic fracture,BMD,EXTENSION,PROBABILITY,FRACTURE INTERVENTION TRIAL,VERTEBRAL FRACTURE,RANDOMIZED-TRIAL,WOMEN,RISK,LONG,ALENDRONATE}}, language = {{eng}}, number = {{3}}, pages = {{1115--1122}}, title = {{Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis}}, url = {{http://doi.org/10.1007/s00198-011-1847-z}}, volume = {{23}}, year = {{2012}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: